NYLIM
NKTR icon

New York Life Investment Management’s Nektar Therapeutics NKTR Stock Holding History

New York Life Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,016
Closed -$238K – 1324
2022
Q4 		$238K Buy
7,016
+791
+13% +$38.3K ﹤0.01% 1161
2022
Q3 		$299K Buy
6,225
+457
+8% +$27.2K ﹤0.01% 1108
2022
Q2 		$329K Buy
+5,768
New +$364K ﹤0.01% 1122

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

New York Life Investment Management's NKTR Position: Q1 2023 in Review

New York Life Investment Management sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 7,016 shares — an estimated $238K sold.

New York Life Investment Management first reported a position in NKTR in Q2 2022 and held it in 3 quarters. The position peaked at $329K in Q2 2022. 195 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

  • New York Life Investment Management reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 7,016 Nektar Therapeutics shares in Q1 2023, an estimated $238K.
  • New York Life Investment Management first reported a position in Nektar Therapeutics in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Nektar Therapeutics position peaked at $329K in Q2 2022.
  • 195 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.